Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.

about

Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.

Item

http://www.wikidata.org/entity/Q35934290

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cost-utility of adjuvant zoled ...... ancer and low estrogen levels.

@ast

Cost-utility of adjuvant zoled ...... ancer and low estrogen levels.

@en

type

Item

label

Cost-utility of adjuvant zoled ...... ancer and low estrogen levels.

@ast

Cost-utility of adjuvant zoled ...... ancer and low estrogen levels.

@en

prefLabel

Cost-utility of adjuvant zoled ...... ancer and low estrogen levels.

@ast

Cost-utility of adjuvant zoled ...... ancer and low estrogen levels.

@en

P1476

Cost-utility of adjuvant zoled ...... ancer and low estrogen levels.

@en

P2093

D Rayson

http://www.w3.org/2001/XMLSchema#string

N W D Lamond

http://www.w3.org/2001/XMLSchema#string

T Younis

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonates and other bone agents for breast cancer

When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.

Development of WHO guidelines on generalized cost-effectiveness analysis.

Willingness to pay for a quality-adjusted life year: in search of a standard.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

P304

e246-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.22.2383

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chris D Skedgel

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281551981

http://www.w3.org/2001/XMLSchema#string

P698

26300674

http://www.w3.org/2001/XMLSchema#string

P932

4530821

http://www.w3.org/2001/XMLSchema#string